



7-604

IFW

PATENT

Docket No. FLO5360.01A1

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicant: KEREN, Gad, et al.
Serial No.: 10/613,654
Filed: July 03, 2003
For: APPARATUS AND METHOD FOR TREATING CONGESTIVE HEART DISEASE
Group: 1614
Examiner:

Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22213-1450

INFORMATION DISCLOSURE STATEMENT

List of Sections Forming Part of This Information Disclosure Statement

The following sections are being submitted for this Information Disclosure Statement:

1. ☒ Preliminary Statements
2. ☒ FORM PTO/SB/08A-PTO/SB/8B
3. ☐ Statement As To Information Material To Examination Not Found In Patents Or Publications
4. ☐ Identification Of Prior Application In Which Listed Information Was Already Cited And For Which No Copies Are Submitted Or Need Be Submitted
5. ☐ Cumulative Patents or Publications
6. ☒ Copies of Listed Information Items Accompanying This Statement
7. ☐ Concise Explanation of Non-English Language Listed Information Items
8. ☐ Translation(s) of Non-English Language Documents
9. ☒ Identification of Person(s) Making This Information Disclosure Statement

Section 1. Preliminary Statements

Applicants submit herewith patents, publications or other information of which they are aware, which they believe may be material to the examination of this application and in respect of which there may be a duty to disclose in accordance with 37 CFR 1.56.

The filing of this information disclosure statement shall not be construed as a representation that a search has been made (37 CFR 1.56(g)), an admission that the information cited is, or is considered to be, material to patentability or that no other material information exists.

The filing of this information disclosure statement shall not be construed as an admission against interest in any manner. Notice of January 9, 1992, 1135 O.G. 13-25, at 25.

Section 2. Form PTO/SB/08A-PTO/SB/08B (substitute for Form 1449)

FORM PTO/SB/08A-PTO/SB/08B IS BEING SUBMITTED HEREWITH IN 13 PAGE(S).

Section 3. Statement As To Information Material To Examination Not Found In Patents Or Publications (Information not listed in PTO SB/08A-PTO SB/08B)

Section 4. Identification of Prior Application in Which Listed Information Was Already Cited and For Which No Copies Are Submitted Or Need Be Submitted

Note: "A copy of any patent, publication or other information listed in an information disclosure statement is not required to be provided if it was previously cited by or submitted to the office in a prior application, provided that the prior application is properly identified in the statement and relied upon for an earlier filing date under 35 U.S.C. 120." 37 CFR 1.98(d).

WARNING: While a copy of a non-English language item of information need not be submitted if its was previously submitted to or cited by the Office in a prior application, provided it is properly identified in this statement and this application relies on that earlier filing date under 35 U.S.C. 120, nevertheless, the requirement in § 1.98(a)(3) for a concise explanation of non-English language information **would not** be satisfied by a statement that a reference was cited in the prosecution of a parent application. The concise explanation must explain the relevance as presently understood by the person designated in § 1.56(c) most knowledgeable about the content of the information. Notice of January 9, 1992, 1135 O.G. 13-25, at 20.

THIS APPLICATION RELIES, UNDER 35 U.S.C. § 120, ON THE EARLIER FILING DATE OF PRIOR APPLICATION _____ FILED ON _____. THE REFERENCES SHOWN IN THE FORM PTO/SB/08A-PTO/SB/08B WERE SUBMITTED TO AND/OR CITED BY THE OFFICE IN THIS PRIOR APPLICATION AND, THEREFORE, ARE NOT REQUIRED TO BE PROVIDED IN THIS APPLICATION.

Section 5. Cumulative Patents or Publications

NOTE: "When the disclosure of two or more patents or publications listed in an information disclosure statement are substantially cumulative, a copy of one of the patents or publications may be submitted without copies of the other patents or publications provided that a statement is made that these other patents or publications are cumulative." 37 CFR 1.98(c).

STATEMENT

_____ is cumulative of the following patents or publications listed on Form PTO
SB/08A:

In accordance with 37 CFR 1.98(c) a copy of only _____ is being submitted with this
information disclosure statement.

Section 6. Copies of Listed Information Items Accompanying This Statement

Legible copies of all items listed accompany this information disclosure statement are enclosed, except for U.S. patents and published applications, and except as indicated below:

☒ **Exception(s) to above**

☒ **US Patents and US Patent Publications are not submitted.**

☐ Cumulative patents or publications identified in Section 5.

It is respectfully stipulated, however, that none of these references teach or render obvious, singly or when considered in combination, applicant's claimed invention. This citation does not constitute an admission that the references are relevant or material to the claims nor that a search has been made; the references are cited only as constituting the closest art of which the applicant is aware.

Section 7. Concise Explanation of Non-English Language Listed Information Items

NOTE: "A concise explanation of the relevance, as it is presently understood by the individual designated in § 1.56(c) most knowledgeable about the information of each patent, publication, or other information listed that is not in the English language **shall** be included in any information disclosure statement filed under § 1.97. "The concise explanation may be either separate from the specification or incorporated therein." 37 CFR 1.98(a)(3).

NOTE: "[T]he explanation required is limited to the relevance as understood by the individual designated in § 1.56(c) most knowledgeable about the content of the information at the time the information is submitted to the Office." Notice of January 9, 1992, 1136 O.G. 13-25, at 14.

NOTE: "Where the information listed is not in the English language, but was cited in a search report by a foreign patent office, the requirement for a concise explanation of relevance is satisfied by submitting an English language version of the search report." Notice of January 9, 1992, 1136 O.G. 13-25, at 14.

NOTE: "The concise explanation requirement for non-English language information may be met by submission of an English language version of the search report indicating the degree of relevance found by the foreign office." Notice of January 9, 1992, 1136 O.G. 13-25, at 20.

WARNING: "The requirement in §1.98(a)(3) for a concise explanation of non-English information **would not** be satisfied by a statement that a reference was cited in the prosecution of a parent application." Notice of January 9, 1992, 1136 O.G. 13-25, at 20 (emphasis added).

PATENT NUMBER DE 43 24 637 A1 DISCLOSES A METHOD AND APPARATUS FOR ORGAN TRANSPLANTATION.

PATENT NUMBER EP 0 654 283 A1 DISCLOSES AN INTRA-AORTIC CATHETER FOR RENAL PERFUSION.

Section 8. Translation(s) of Non-English Language Documents

NOTE: "If a written English language translation of a non-English language document, or portion thereof, is within the possession, custody or control of, or is readily available to any individual designated in § 1.56(c), a copy of the translation shall accompany the statement." 37 CFR 1.98(c).

NOTE: "The Office does not intend to require translations unless they have been reduced to writing and are actually translations of what is contained in non-English language information. Applicants should note, however, that most examiners do not have the ability to understand information which is not English and the that Office will not routinely translate information submitted in a non-English language. The examiner will consider the information insofar as it is understood on its face, e.g., drawings, chemical formulas, English-language abstracts, but will not have the information translated unless it appears to be necessary to do so. Applicants are required to aid the examiner by complying with the requirements of a concise explanation in § 1.98(a)(3) for information submitted in a non-English language." Notice of January 9, 1992, 1135 O.G. 13-25, at 21.

☒ No English language translations of the foreign language patents, publications or information or parts thereof are readily available, except for those listed above.

☐ The following foreign language documents submitted are believed to be the equivalent or substantial equivalent of the English language documents identified below, which are also submitted herewith.

☐ Submitted herewith is an English language translation of the following foreign patents, publications or information or of those portions of those patents, publications or information considered to be material:

Section 9. Signature of Attorney

Dated:

7/1/08

Reg. No.:

33,201

Tel. No.:

(916) 498-1010


SIGNATURE OF ATTORNEY

John P. O'Banion
O'BANION & RITCHEY LLP
400 Capitol Mall, Suite 1550
Sacramento, CA 95814



TRANSMITTAL OF INFORMATION DISCLOSURE STATEMENT
(Under 37 CFR 1.97(b) or 1.97(c))

Docket No.
FLO5360.1A1

In Re Application Of: **KEREN, Gad, et al.**

Serial No.
10/613,654

Filing Date
July 03, 2003

Examiner

Group Art Unit
1614

Title: **APPARATUS AND METHOD FOR TREATING CONGESTIVE HEART DISEASE**

Address to:
Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

37 CFR 1.97(b)

1. ☒ The Information Disclosure Statement submitted herewith is being filed within three months of the filing of a national application other than a continued prosecution application under 37 CFR 1.53(d); within three months of the date of entry of the national stage as set forth in 37 CFR 1.491 in an international application; before the mailing of a first Office Action on the merits, or before the mailing of a first Office Action after the filing of a request for continued examination under 37 CFR 1.114.

37 CFR 1.97(c)

2. ☐ The Information Disclosure Statement submitted herewith is being filed after the period specified in 37 CFR 1.97(b), provided that the Information Disclosure Statement is filed before the mailing date of a Final Action under 37 CFR 1.113, a Notice of Allowance under 37 CFR 1.311, or an Action that otherwise closes prosecution in the application, and is accompanied by one of:

☐ the statement specified in 37 CFR 1.97(e);

OR

☐ the fee set forth in 37 CFR 1.17(p).



TRANSMITTAL OF INFORMATION DISCLOSURE STATEMENT (Under 37 CFR 1.97(b) or 1.97(c))	Docket No. FLO5360.1A1
---	---------------------------

In Re Application: **KEREN, Gad, et al.**

Serial No. 10/613,654	Filing Date July 03, 2003	Examiner	Group Art Unit 1614
--------------------------	------------------------------	----------	------------------------

APPARATUS AND METHOD FOR TREATING CONGESTIVE HEART DISEASE

Payment of Fee
(Only complete if Applicant elects to pay the fee set forth in 37 CFR 1.17(p))

- ☐ A check in the amount of _____ is attached.
- ☒ The Director is hereby authorized to charge and credit Deposit Account No. **07-1137** as described below.
- ☐ Charge the amount of _____
- ☐ Credit any overpayment.
- ☒ Charge any additional fee required.

Certificate of Transmission by Facsimile*

I certify that this document and authorization to charge deposit account is being facsimile transmitted to the United States Patent and Trademark Office (F:

(Date)

Signature

Typed or Printed Name of Person Signing Certificate

Certificate of Mailing by First Class Mail

I certify that this document and fee is being deposited on _____ with the U.S. Postal Service as first class mail under 37 C.F.R. 1.8 and is addressed to the Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

Signature of Person Mailing Correspondence

Typed or Printed Name of Person Mailing Certificate


*This certificate may only be used if paying by deposit account.

Signature

Dated: **7/1/04**

John P. O'Banion, Reg. No. 33,201
O'BANION & RITCHEY LLP
400 Capitol Mall, Suite 1550
Sacramento, CA 95814
(916) 498-1010

cc:



CERTIFICATION UNDER 37 CFR 1.10

I hereby certify that the foregoing:

Information Disclosure Statement

is being deposited with the United States Postal Service on 7/1/04 in an envelope as "Express Mail Post Office to Addressee" Mailing Label Number EV352302469US addressed to the: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

JOHN P. O'BANION

(Type or print name of person mailing paper)


(Signature of person mailing paper)



CERTIFICATION UNDER 37 CFR 1.10

I hereby certify that the foregoing:

Transmittal of Information Disclosure Statement Under 37CFR 1.97(b) or
1.97(c)

is being deposited with the United States Postal Service on 7/1/04 in an
envelope as "Express Mail Post Office to Addressee" Mailing Label Number
EV352302469US addressed to the: Commissioner for Patents, P.O. Box 1450,
Alexandria, VA 22313-1450.

JOHN P. O'BANION

(Type or print name of person mailing paper)


(Signature of person mailing paper)



CERTIFICATION UNDER 37 CFR 1.10

I hereby certify that the foregoing:

Form 1449

is being deposited with the United States Postal Service on 7/1/04 in an envelope as "Express Mail Post Office to Addressee" Mailing Label Number EV352302469US addressed to the: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

JOHN P. O'BANION

(Type or print name of person mailing paper)


(Signature of person mailing paper)



CERTIFICATION UNDER 37 CFR 1.10


I hereby certify that the foregoing:


Cited References (190)

is being deposited with the United States Postal Service on 7/4/04 in an envelope as "Express Mail Post Office to Addressee" Mailing Label Number EV352302469US addressed to the: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

JOHN P. O'BANION

(Type or print name of person mailing paper)


(Signature of person mailing paper)



PTO/SB/08A (08-03)

Approved for use through 07/31/2006. OMB 0651-0031
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449/PTO

**INFORMATION DISCLOSURE
STATEMENT BY APPLICANT**

(Use as many sheets as necessary)

Complete if Known

Application Number	10/613,654
Filing Date	07/03/03
First Named Inventor	KEREN, ET AL.
Art Unit	
Examiner Name	
Attorney Docket Number	FL05360.01A1

Sheet 1 of 13

U. S. PATENT DOCUMENTS

Examiner Initials*	Cite No. ¹	Document Number	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
		Number-Kind Code ² (if known)			
		US- 2,499,045	02/01/1950	F,R, WALKER ET AL,	
		US- 3,455,298	07/1969	Anstadt	
		US- 3,516,408	06/01/1970	V. L. Montanti	
		US- 3,667,069	06/01/1972	Blackshear et al.	
		US- 3,730,186	05/1973	Edmunds, Jr. et al.	
		US- 3,791,374	02/01/1974	Guarino	
		US- 3,995,623	12/01/1976	BLAKE ET AL,	
		US- 4,309,994	01/01/1982	Grunwald	
		US- 4,345,602	08/01/1982	Yoshimura et al.	
		US- 4,407,271	10/01/1983	Schiff	
		US- 4,423,725	01/01/1984	Baran et al.	
		US- 4,459,977	07/01/1984	PIZON ET AL,	
		US- 4,490,374	12/01/1984	BANDURCO ET AL,	
		US- 4,493,697	01/01/1985	KRAUSE ET AL,	
		US- 4,536,893	08/1985	Parravicini	
		US- 4,546,759	10/1985	Solar	
		US- 4,554,284	11/01/1985	STRINGER ET AL,	
		US- 4,685,446	08/1987	Choy	
		US- 4,705,502	11/01/1987	PATEL	

FOREIGN PATENT DOCUMENTS

Examiner Initials*	Cite No. ¹	Foreign Patent Document	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages Or Relevant Figures Appear	T ⁶
		Country Code ³ Number ⁴ Kind Code ⁵ (if known)				
		DE 43 24 637 AI	03/09/1995	Schreiber		
		EP 0 654 283 AI	05/24/1995	Anaya F. de Lomana		
		WO 98/03213	01/29/1998	Stevens, et al.		
		WO 98/17347	04/30/1998	Tsitlik, et al.		
		WO 98/52639	11/26/1998	Hinchliffe		
		EP 0 884 064 A2	12/16/1998	Forman, et al.		

Examiner
SignatureDate
Considered

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. ¹ Applicant's unique citation designation number (optional). ² See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. ⁶ Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449/PTO		Complete if Known	
INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use as many sheets as necessary)		Application Number	10/613,654
		Filing Date	07/03/03
		First Named Inventor	KEREN, ET AL.
		Art Unit	
		Examiner Name	
Sheet	2	of	13
		Attorney Docket Number	FL 05360.01A1

U. S. PATENT DOCUMENTS					
Examiner Initials*	Cite No. ¹	Document Number	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
		Number-Kind Code ² (if known)			
		US- 4,705,507	11/01/1987	BOYLES	
		US- 4,712,551	12/01/1987	Rayhanabad	
		US- 4,714,460	12/01/1987	CALDERON	
		US- 4,723,939	02/01/1988	ANAISE	
		US- 4,753,221	06/01/1988	KENSEY ET AL.	
		US- 4,781,716	11/1988	Richelsoph	
		US- 4,817,586	04/1989	Wampler	
		US- 4,834,707	05/1989	Evans	
		US- 4,846,831	07/1989	Skillin	
		US- 4,861,330	08/1989	Voss	
		US- 4,863,461	09/1989	Jarvik	
		US- 4,888,011	12/1989	Kung et al.	
		US- 4,902,272	02/1990	Milder et al.	
		US- 4,902,291	02/1990	Kolff	
		US- 4,906,229	03/1990	Wampler	
		US- 4,909,252	03/01/1990	Goldberger	606/194
		US- 4,911,163	03/01/1990	FINA	
		US- 4,919,647	04/01/1990	Nash	600/16
		US- 4,925,377	05/1990	Inacio et al.	

FOREIGN PATENT DOCUMENTS						
Examiner Initials*	Cite No. ¹	Foreign Patent Document	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages Or Relevant Figures Appear	T ⁶
		Country Code ³ ~Number ⁴ ~Kind Code ⁵ (if known)				
		WO 99/22784	05/14/1999	Howansky, et al.		
		WO 99/33407	07/08/1999	Sterman		
		WO 99/51286	10/14/1999	Talpade		
		WO 00/41612	07/20/2000	Keren, et al.		
		WO 01/083016	04/27/2001	Keren, et al.		
		WO 01/41861 A1	06/2001	Levin, et al		

Examiner Signature	Date Considered
--------------------	-----------------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. ¹ Applicant's unique citation designation number (optional). ² See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. ⁶ Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND

TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449/PTO <h2 style="text-align: center; margin: 0;">INFORMATION DISCLOSURE STATEMENT BY APPLICANT</h2> <p style="text-align: center; margin: 0;">(Use as many sheets as necessary)</p>				Complete if Known	
		Application Number	10/613,654		
		Filing Date	07/03/03		
		First Named Inventor	KEREN, ET AL.		
		Art Unit			
		Examiner Name			
		Attorney Docket Number	FLO5360.01A1		
Sheet	3	of	13		

U. S. PATENT DOCUMENTS					
Examiner Initials*	Cite No. ¹	Document Number	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
		Number-Kind Code ² (if known)			
		US- 4,925,443	05/1990	Heilman et al.	
		US- 4,927,407	05/01/1990	DORMAN	
		US- 4,927,412	05/01/1990	MENASCHE	
		US- 4,938,766	07/01/1990	Jarvik, Robert K.	
		US- 4,950,226	08/01/1990	BARRON	
		US- 4,957,477	09/01/1990	Lundback	
		US- 4,964,864	10/01/1990	Summers et al.	
		US- 4,976,691	12/01/1990	Sahota, Harvinder	
		US- 4,976,692	12/01/1990	ATAD	
		US- 4,990,139	02/01/1991	JANG	
		US- 4,995,864	02/01/1991	Bartholomew et al.	
		US- 5,002,531	03/01/1991	Bonzel	604/96
		US- 5,002,532	03/01/1991	GAISER ET AL.	604/101
		US- 5,053,023	10/1991	Martin	604/280
		US- 5,059,178	10/01/1991	YA	
		US- 5,067,960	11/01/1991	Grandjean	
		US- 5,069,680	12/01/1991	Grandjean	
		US- 5,073,094	12/01/1991	Dorman et al.	
		US- 5,089,019	02/01/1992	Grandjean	

FOREIGN PATENT DOCUMENTS						
Examiner Initials*	Cite No. ¹	Foreign Patent Document	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages Or Relevant Figures Appear	T ⁶
		Country Code ³ Number ⁴ Kind Code ⁵ (if known)				

Examiner Signature		Date Considered	
-----------------------	--	--------------------	--

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. ¹ Applicant's unique citation designation number (optional). ² See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. ⁶ Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449/PTO

**INFORMATION DISCLOSURE
STATEMENT BY APPLICANT**

(Use as many sheets as necessary)

Sheet 4 of 13

Complete if Known

Application Number	10/613,654
Filing Date	07/03/03
First Named Inventor	KEREN, ET AL.
Art Unit	
Examiner Name	
Attorney Docket Number	FLO5360.01A1

U. S. PATENT DOCUMENTS

Examiner Initials*	Cite No. ¹	Document Number	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
		Number-Kind Code ² (if known)			
		US- 5,098,370	03/01/1992	RAHAT ET AL,	
		US- 5,098,442	03/1992	Grandjean	
		US- 5,112,301	05/01/1992	Fenton et al.	
		US- 5,112,349	05/01/1992	Summers et al.	623/3
		US- 5,119,804	06/1992	Anstadt	
		US- 5,129,883	07/01/1992	BLACK	
		US- 5,131,905	07/1992	Grooters	
		US- 5,135,474	08/01/1992	SWAN ET AL,	
		US- 5,158,540	10/01/1992	WIJAY ET AL,	
		US- 5,163,910	11/01/1992	SCHWARTZ ET AL,	
		US- 5,167,628	12/1992	Boyles	
		US- 5,180,364	01/01/1993	Ginsburg, Robert	
		US- 5,205,810	04/1993	Guiraudon et al.	
		US- 5,226,888	07/01/1993	Arney	604/96
		US- 5,256,141	10/01/1993	GENCHEFF ET AL,	
		US- 5,257,974	11/1993	Cox	604/96
		US- 5,282,784	02/01/1994	Willard	604/8
		US- 5,290,227	03/1994	Pasque	
		US- 5,308,319	5/1994	Ide et al.	600/18

FOREIGN PATENT DOCUMENTS

Examiner Initials*	Cite No. ¹	Foreign Patent Document	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages Or Relevant Figures Appear	T ⁶
		Country Code ³ -Number ⁴ -Kind Code ⁵ (if known)				
	4					
	4					
	4					
	4					
	4					
	4					

Examiner
SignatureDate
Considered

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. ¹ Applicant's unique citation designation number (optional). ² See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. ⁶ Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND

TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449/PTO		Complete if Known	
INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use as many sheets as necessary)		Application Number	10/613,654
		Filing Date	07/03/03
		First Named Inventor	KEREN, ET AL.
		Art Unit	
		Examiner Name	
Sheet 5 of 13	Attorney Docket Number	FLO5360.01A1	

U. S. PATENT DOCUMENTS					
Examiner Initials*	Cite No. ¹	Document Number	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
		Number-Kind Code ² (if known)			
		US- 5,308,320	05/1994	Safar et al.	
		US- 5,312,343	05/01/1994	KROG ET AL,	
		US- 5,320,604	06/01/1994	WALKER ET AL,	
		US- 5,326,374	07/1994	Ilbawi et al.	
		US- 5,328,470	07/01/1994	NABEL ET AL,	
		US- 5,332,403	07/1994	Kolff	
		US- 5,358,519	10/1994	Grandjean	
		US- 5,364,337	11/1994	Guiraudon et al.	
		US- 5,370,617	12/06/1994	Sahota	
		US- 5,383,840	01/01/1995	Heilman et al.	
		US- 5,397,307	03/01/1995	GOODIN	
		US- 5,429,584	07/1995	Chiu	
		US- 5,453,084	09/01/1995	Moses	
		US- 5,464,449	11/01/1995	RYAN ET AL,	
		US- 5,478,331	12/26/1995	Helflin et al.	
		US- 5,484,385	01/01/1996	RISHTON	
		US- 5,505,701	04/01/1996	Anaya Fernandez de Lomana	604/99
		US- 5,509,428	04/01/1996	Dunlop	128/898
		US- 5,536,250	07/16/1996	Klein et al.	

FOREIGN PATENT DOCUMENTS					
Examiner Initials*	Cite No. ¹	Foreign Patent Document	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages Or Relevant Figures Appear
		Country Code ³ Number ⁴ Kind Code ⁵ (if known)			

Examiner Signature	Date Considered
--------------------	-----------------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. ¹ Applicant's unique citation designation number (optional). ² See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. ⁶ Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT <i>(Use as many sheets as necessary)</i>				Complete if Known	
		Application Number	10/613,654		
		Filing Date	07/03/03		
		First Named Inventor	KEREN, ET AL.		
		Art Unit			
		Examiner Name			
		Attorney Docket Number	FLO5360.01A1		
Sheet	6	of	13		

U. S. PATENT DOCUMENTS					
Examiner Initials*	Cite No. ¹	Document Number	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
		Number-Kind Code ² (if known)			
		US- 5,558,617	09/1996	Heilman et al.	
		US- 5,599,306	02/01/1997	Klein et al.	
		US- 5,609,628	03/01/1997	KERANEN	
		US- 5,613,949	03/01/1997	Miraki	
		US- 5,617,878	04/01/1997	TAHERI	
		US- 5,643,171	07/01/1997	Bradshaw et al.	600/1
		US- 5,643,215	07/01/1997	FUHRMAN ET AL,	
		US- 5,702,343	12/1997	Alferness	
		US- 5,713,860	02/03/1998	Kaplan et al.	
		US- 5,720,735	02/01/1998	Dorros	
		US- 5,755,779	05/01/1998	HORIGUCHI	
		US- 5,762,599	06/01/1998	SOHN	
		US- 5,776,190	07/1998	Jarvik	
		US- 5,797,876	08/01/1998	SPEARS ET AL,	
		US- 5,902,229	05/1999	Tsitlik et al.	
		US- 5,902,336	05/01/1999	MISHKIN	
		US- 5,913,852	6/1999	Magram	
		US- 5,928,132	07/01/1999	LESCHINSKY	
		US- 5,935,924	08/1999	Bunting et al.	

FOREIGN PATENT DOCUMENTS						
Examiner Initials*	Cite No. ¹	Foreign Patent Document	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages Or Relevant Figures Appear	T ⁶
		Country Code ³ -Number ⁴ -Kind Code ⁵ (if known)				

Examiner Signature		Date Considered	
--------------------	--	-----------------	--

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. ¹ Applicant's unique citation designation number (optional). ² See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. ⁶ Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449/PTO

**INFORMATION DISCLOSURE
STATEMENT BY APPLICANT**

(Use as many sheets as necessary)

Complete if Known

Sheet	7	of	13	Application Number	10/613,654
				Filing Date	07/03/03
				First Named Inventor	KEREN, ET AL.
				Art Unit	
				Examiner Name	
				Attorney Docket Number	FLO5360.01A1

U. S. PATENT DOCUMENTS

Examiner Initials*	Cite No. ¹	Document Number Number-Kind Code ² (if known)	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
		US- 5,971,910	10/1999	Tsitlik et al.	
		US- 5,984,955	11/01/1999	WISSELINK	
		US- 6,039,721	03/21/2000	Johnson et al.	
		US- 6,077,256	06/01/2000	Mann	
		US- 6,086,527	07/01/2000	Talpade	600/18
		US- 6,117,117	09/01/2000	Mauch	
		US- 6,387,037	05/14/2002	Bolling et al.	
		US- 6,390,969	05/21/2002	Bolling et al.	
		US- 6,508,787	01/21/2003	Erbel et al.	
		US- 1,696,018	12/01/1928	Schellberg	
		US- 5,345,927	09/01/1994	Bonutti	
		US-			
		US-			
		US-			
		US-			
		US-			
		US-			
		US-			
		US-			

FOREIGN PATENT DOCUMENTS

Examiner Initials*	Cite No. ¹	Foreign Patent Document Country Code ³ -Number ⁴ -Kind Code ⁵ (if known)	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages Or Relevant Figures Appear	T ⁶

Examiner Signature	Date Considered
--------------------	-----------------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. ¹ Applicant's unique citation designation number (optional). ² See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. ⁶ Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT <i>(Use as many sheets as necessary)</i>			Complete if Known		
			Application Number	10/613,654	
			Filing Date	07/03/2003	
			First Named Inventor	KEREN, et al.	
			Art Unit		
			Examiner Name		
Sheet	8	of	13	Attorney Docket Number	FLO5360.01A1

NON PATENT LITERATURE DOCUMENTS			
Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
		MARGULIES, et al., Intra-Arterial Atrial Natriuretic Factor (ANF) Attenuates Radiocontrast-Induced etc., Renal Pathology, unknown date, pp. 666, Abstract only	
		DEL GRECO, The Kidney in Congestive Heart Failure, Modern Concepts of Cardiovascular Disease, Sept. 1975, Vol 44, No. 9, pp. 47-52	
		Bischoff, W. et al.; "MODIFIED IN SITU PERFUSION OF THE KIDNEY USING BALLOON CATHETERS," Vol. 94, No. 30, pp. 1695-1697, October 21, 1976. ABSTRACT ONLY.	
		Eisenberger, F. et al.; "TRANSFEMORAL CANNULATION OF THE RENAL VESSELS. DIAGNOSTIC AND THERAPEUTIC USE IN UROLOGY," Urology [A], Vol. 16, No. 1, pp. 1-5, January, 1977. ABSTRACT ONLY.	
		Linden, R.J. et al.; "THE NATURE OF THE ATRIAL RECEPTORS RESPONSIBLE FOR A REFLEX DECREASE IN ACTIVITY IN RENAL NERVES IN THE DOG," The Physiological Society, pp. 31-40, (1980).	
		EISENBERG, et al., Renal Failure After Major Angiography, Am J Med, Jan. 1980, Vol. 68, pp. 43-46	
		EISENBERG, et al., Renal Failure after Major Angiography Can be Avoided with Hydration, AJR, May 1981; 136:859-861	
		THOMAS, et al. Influence of Bradykinin and Papaverine on Renal etc., Renal Physiology, Basel 5:197-205 (1982)	
		D'ELIA, et al., Nephrotoxicity from angiographic Contrast Material, "A prospective Study, Am J Med, May 1982, Vol. 72, pp. 719-725	
		Seiter, H. et al.; "MODIFIED T-CATHETER AND ITS USE FOR TRANSVENOUS HYPOTHERMIC IN SITU PERFUSION IN THE SURGICAL RESTORATION OF THE KIDNEY WITH STAGHORN CALCULI," Z. Urol Nephrol., Vol. 76, No. 6, pp. 403-406, June, 1983. ABSTRACT ONLY.	

Examiner Signature		Date Considered	
--------------------	--	-----------------	--

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Applicant's unique citation designation number (optional). ² Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT <i>(Use as many sheets as necessary)</i>			Complete if Known		
			Application Number	10/613,654	
			Filing Date	07/03/2003	
			First Named Inventor	KEREN, et al.	
			Art Unit		
			Examiner Name		
Sheet	9	of	13	Attorney Docket Number	FLO5360.01A1

NON PATENT LITERATURE DOCUMENTS			
Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
		THOMAS, et al. Glomerular filtration dynamics during renal vasodilation etc. Am. J. Physiol. 244:F606-F611 (1983)	
		ELKAYAM, et al., Renal Hemodynamic Effects of Vasodilation with Nifedipine and Hydralazine in Patients With Heart Failure, JACC Dec 1984;Vol 4, No. 6, pp. 1261-1267	
		Kehrer, G. et al.; "CONSTRUCTION AND EXPERIMENTAL APPLICATION OF A CATHETER FOR SELECTIVE ARTERIAL KIDNEY PERFUSION IN SITU," Urol. Res., Vol. 13, No. 2, pp. 85-89,(1985). ABSTRACT ONLY.	
		MASON, et al., Renal Dysfunction After Arteriography, JAMA, 1985;253:1001-1004	
		Walker, H.S. et al.; "USE OF A BALLOON-TIPPED PERFUSION CATHETER FOR RENAL PRESERVATION DURING SUPRARENAL ABDOMINAL AORTIC OPERATIONS," J. Vasc. Surg., Vol. 2, No. 2, pp. 337-339, March, 1985. ABSTRACT ONLY.	
		TALIERCIO, et al., Risks for Renal Dysfunction with Cardiac Angiography, Annals of Internal Medicine, 1986;104:501-504	
		LASS, et al., Cardiovascular and Renal Hemodynamic Effects of Intravenous Infusions of the Selective DA1 Agonist etc., Circulation 1988;78:1310-1315	
		VARI et al., Induction , prevention and mechanisms of contrast media-induced acute renal failure, Kidney International, 1988; 33:669-707	
		PARFREY, et al., Contrast Material-Induced Renal Failure in Patients with Diabetes Mellitus, Renal Insufficiency, or Both, N Engl J Med 1989; 320:143-149	
		SCHWAB, et al., Contrast Nephrotoxicity: A Randomized Controlled Trial of a Nonionic and an Ionic Radiographic Contrast Agent, N Engl J Med, 1989, 320:149-153	

Examiner Signature	Date Considered
--------------------	-----------------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Applicant's unique citation designation number (optional). ² Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT <i>(Use as many sheets as necessary)</i>				Complete if Known	
				Application Number	10/613,654
				Filing Date	07/03/2003
				First Named Inventor	KEREN, et al.
				Art Unit	
				Examiner Name	
Sheet	10	of	13	Attorney Docket Number	FLO5360.01A1

NON PATENT LITERATURE DOCUMENTS			
Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
		MARGULIES, et al., Induction and prevention of radiocontrast-induced nephropathy in dogs with heart failure, Kidney Int. 1990; Vol. 38:1101-1108	
		Akaba, N. et al.; "A CYLINDER-SHAPED BALLOON CATHETER FOR THE MANAGEMENT OF DISSECTING ANEURYSMS IN ACUTE STAGE," Herz, Vol. 17, No. 6, pp. 390-393, December, 1992. ABSTRACT ONLY.	
		Kobayashi, A. et al.; "EXPERIMENTAL STUDY ON THE USEFULNESS OF THE AUTOPERFUSION BALLOON CATHETER IN MAINTAINING THE BLOOD SUPPLY TO THE DISTAL ORGANS," Nippon Igaku Hoshasen Gakkai Zasshi, Vol. 52, No. 5, pp. 682-684, May	
		Williams, D.M. et al.; "DESIGN AND TESTING OF A HIGH-FLO2 AUTOPERFUSION CATHETER: AN EXPERIMENTAL STUDY," J. Vasc. Interv. Radiol., Vol. 3, NO. 2, pp. 285-290, May, 1992. ABSTRACT ONLY.	
		Katsumata, T. et al.; "NEWLY-DEVELOPED CATHETER FOR CARDIO-RENAL ASSIST DURING INTRAAORTIC BALLOON COUNTERPULSION," Kyobu Geka, Vol. 46, No. 9, pp. 767-770, August, 1993. ABSTRACT ONLY.	
		PATEL, et al. Intravenous Fenoldopam Infusion in Severe Heart Failure, Cardiovasc Drugs Ther 1993;7:97-101	
		SHUSTERMAN, et al. Fenoldopam, But Not Nitroprusside, Improves Renal Function etc. Am J of Medicine, 95:161-168 (1993)	
		Novick, A.C.; "ATHEROSCLEROTIC ISCHEMIC NEPHROPATHY. EPIDEMIOLOGY AND CLINICAL CONSIDERATIONS," Urol. Clin. North Am, Vol. 21, No. 2, pp. 195-200, May, 1994. ABSTRACT ONLY	
		SOLOMON, et al., Effects of Saline, Mannitol, and Furosemide on Acute Decreases in Renal Function etc., N Engl J Med 1994; Vol 331 No. 21 pp. 1416-1420	
		STRICK, et al., Direct measurement of renal medullary blood flow in the dog, Am J. Physiol. 267 (Regulatory Integrative Comp. Physiol. 36): R253-R2259, 1994	

Examiner Signature		Date Considered	
--------------------	--	-----------------	--

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Applicant's unique citation designation number (optional). ² Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT <i>(Use as many sheets as necessary)</i>				Complete if Known	
				Application Number	10/613,654
				Filing Date	07/03/2003
				First Named Inventor	KEREN, et al.
				Art Unit	
				Examiner Name	
Sheet	11	of	13	Attorney Docket Number	FLO5360.01A1

NON PATENT LITERATURE DOCUMENTS			
Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
		Levin, Howard R. et al.; "REVERSAL OF CHRONIC VENTRICULAR DILATION IN PATIENTS WITH END-STAGE CARDIOMYOPATHY BY PROLONGED MECHANICAL UNLOADING," Vol. 91, No. 11, pp. 2717-2718, June 1, 1995.	
		Masaki, Z. et al.; "IN-SITU PERFUSION BY RETROGRADE CANNULATION OF A TUMOR ARTERY FOR NEPHRON-SPARING SURGERY," Int. J. Urol, Vol. 2, No. 3, pp. 161-165, July, 1995. ABSTRACT ONLY.	
		RUDNICK, et al., Nephrotoxicity of ionic and nonionic contrast media in 1196 patients: A randomized trial, Kidney International, 1995;47:254-261	
		Cohn, Jay N.; "THE MANAGEMENT OF CHRONIC HEART FAILURE," The New England Journal of Medicine, pp. 490-498, August 15, 1996.	
		ELKAYAM, et al., Renal Vasodilatory Effect of Endothelial Stimulation in Patients with Chronic Congestive Heart Failure, J Am Coll Cardiol 1996;28:176-182	
		Iannone, L.A. et al - "EFFECT OF PRIMARY BALLOON EXPANDABLE RENAL ARTERY STENTS ON LONG-TERM PATENCY RENAL FUNCTION AND BLOOD PRESSURE IN HYPERTENSIVE AND RENAL INSUFFICIENT PATIENTS WITH RENAL ARTERY STENOSIS," Cathet. Cardiovasc.	
		Greco, B.A. et al.; "ATHEROSCLEROTIC ISCHEMIC RENAL DISEASE," Am J. Kidney Dis., Vol. 29, No. 2, pp. 167-187, Feb., 1997. ABSTRACT ONLY.	
		MCCARTHY, Animal Models in Medical Device Development and Qualification, Charles River laboratories, Vol 10(2) 1997	
		MCCULLOUGH, et al., Acute Renal Failure after Coronary Intervention: Incidence, Risk Factors, and Relationship to Mortality, Am J Med. 1997;103:368-375	
		White, C.J. et al.; "RENAL ARTERY STENT PLACEMENT: UTILITY IN LESIONS DIFFICULT TO TREAT WITH BALLOON ANGIOPLASTY," J. Am. Coll. Cardiol., Vol. 30, No. 6, pp. 1445-1450, November 15, 1997. ABSTRACT ONLY	

Examiner Signature		Date Considered	
--------------------	--	-----------------	--

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Applicant's unique citation designation number (optional). ² Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT <i>(Use as many sheets as necessary)</i>				Complete if Known	
				Application Number	10/613,654
				Filing Date	07/03/2003
				First Named Inventor	KEREN, et al.
				Art Unit	
				Examiner Name	
Sheet	12	of	13	Attorney Docket Number	FLO5360.01A1

NON PATENT LITERATURE DOCUMENTS			
Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
		Canaud, B. et al.; "TEMPORARY VASCULAR ACCESS FOR EXTRACORPOREAL RENAL REPLACEMENT THERAPIES IN ACUTE RENAL FAILURE PATIENTS," Kidney Int. Suppl., Vol. 66, pp. S142-S150, May, 1998. ABSTRACT ONLY	
		DRESCHER, et al., Prevention of Contrast Medium-Induced Renal Vasospasm by Phosphodiesterase Inhibition, Invest Radiol 1998;33:858-862	
		Garwood, Susan et al.; "RENAL PRESERVATION STRATEGIES FOR HIGH RISK PATIENTS," University of Chico School of Medicine, Cover Page, Table of Contents Page, pp. 1-19, (1998).	
		Jacobs, M.J. et al.; "REDUCED RENAL FAILURE FOLLOWING THORACOABDOMINAL AORTIC ANEURYSM REPAIR BY SELECTIVE PERFUSION," Eur. J. Cardiothorac. Surg., Vol. 14, No. 2, pp. 201-5, August, 1998. ABSTRACT ONLY	
		Mathis, J.M. et al.; "USE OF A GUIDE CATHETER AS A TEMPORARY STENT DURING MICROCATETER INTERVENTION," AJNR Am. J. Neuroradiol, Vol. 19, No. 5, pp. 932-933, May, 1998. ABSTRACT ONLY.	
		Middleton, J.P.; "ISCHEMIC DISEASE OF THE KIDNEY: HOW AND WHY TO CONSIDER REVASCULARIZATION," J. Nephrol., Vol. 11, No. 3, pp. 123-136, May-June, 1998. ABSTRACT ONLY.	
		Postma, C.T. et al.; "TREATMENT OF RENAL ARTERY STENOSIS WITH INTRA-ARTERIAL STENTS," Ned Tijdschr Geneesk, Vol. 142, No. 39, pp. 2132-7, September 26, 1998. ABSTRACT ONLY	
		BAKRIS, et al., Renal hemodynamics in radiocontrast medium-induced renal dysfunction etc. Kidney International, Vol. 56 pp. 206-210 (1999)	
		Bergey, E.A. et al.; "TRANSHEPATIC INSERTION OF VASCULAR DIALYSIS CATHETERS IN CHILDREN: A SAFE, LIFE-PROLONGING PROCEDURE," Pediatr. Radiol., Vol. 29, No. 1, pp. 42-50, Jan. 1999. ABSTRACT ONLY	
		Fox, S. I.; "MECHANISMS OF CONTRACTION," Human Physiology, Fourth Edition, pp. 300-323.	

Examiner Signature	Date Considered
--------------------	-----------------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Applicant's unique citation designation number (optional). ² Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT <i>(Use as many sheets as necessary)</i>			Complete if Known		
			Application Number	10/613,654	
			Filing Date	07/03/2003	
			First Named Inventor	KEREN, et al.	
			Art Unit		
			Examiner Name		
Sheet	13	of	13	Attorney Docket Number	FLO5360.01A1

NON PATENT LITERATURE DOCUMENTS			
Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
		HEYMAN, et al., Pathophysiology of Radiocontrast Nephropathy, A Role for Medullary Hypoxia, Invest Radiol, 1999;34:685-691	
		KIM et al. Fluoroscopic Landmarks for Optimal Visualization of the Proximal Renal Arteries, JVIR, 10:37-39 (1999)	
		STEVENS, et al., A Prospective Randomized Trial of Prevention Measures in Patients at High Risk for Contrast Nephropathy, J Am Coll Cardiol, 1999;33:403-411	

Examiner Signature		Date Considered	
--------------------	--	-----------------	--

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Applicant's unique citation designation number (optional). ² Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.